Compare Vanguard Total International Stock Index Fund ETF (VXUS) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vanguard Total International Stock Index Fund ETF vs Zoetis Inc — how do they compare? Vanguard Total International Stock Index Fund ETF trades at $84.71 (market cap $665.70B), while Zoetis Inc trades at $73.02 (market cap $30.20B). The key difference: Vanguard Total International Stock Index Fund ETF is far larger — about 22× Zoetis Inc's market cap, and Zoetis Inc pays a 2.9% dividend while Vanguard Total International Stock Index Fund ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Vanguard Total International Stock Index Fund ETF for 55 Days and Zoetis Inc for 70 Days on average.
| VXUS | ZTS | |
|---|---|---|
Market Cap | $665.70B | $30.20B |
Volume | 4,864,744 | 6,175,327 |
Sector | Sector/Thematic | Health |
52-Week High | $88.41 | $147.53 |
52-Week Low | $72.17 | $69.09 |
Typical Hold Time | 55 Days | 70 Days |
Enterprise Value | — | $37.76B |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
VXUS trades at $84.78, down 1.19% with a bearish technical signal from moving averages. The ETF provides broad international stock exposure outside the U.S., with institutional buying interest noted in recent SEC filings. Technical indicators show neutral oscillators but bearish momentum signals from ADX readings.
The fund offers diversification benefits as a core international holding, though recent performance faces headwinds. Key risks include currency fluctuations and emerging market volatility. Long-term outlook remains positive for global equity exposure, supported by Vanguard's low-cost structure and comprehensive market coverage.
Zoetis (ZTS) trades at $71.55, showing modest daily gains of 0.32% amid a challenging market environment. The stock faces bearish technical signals with mixed quarterly earnings performance - beating expectations in Q2 2026 but missing in Q1. Strong fundamentals persist with 71.67% gross margins and 27.69% net income margins, though recent headwinds include U.S. companion animal market weakness and increased competition in key therapeutic areas. The company maintains robust cash flow generation with $2.9 billion from operations in 2025.
Despite near-term pressures, ZTS presents value opportunity with attractive valuation at 11.67 P/E ratio and consensus price target of $87.33 suggesting 22% upside. Risks include ongoing competitive pressures and U.S. market softness, but industry-leading profitability and international growth provide stability. Analyst sentiment remains positive with no sell ratings among 32 covering firms, though technical indicators suggest cautious near-term positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Vanguard Total International Stock Index Fund ETF
VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.
Read more on VXUS →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
